trial · primary record
Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
Breast Cancer Invasive
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 160 |
| Primary completion | 2031-01-31 |
| Primary endpoint | Residual Cancer Burden 0/1 rate as assessed by independent central review |
| Registry ID | NCT06144944 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:50.711Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06144944
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.